Search clinical trials for: CV301, NSCLC, Pembrolizumab, Nivolumab

Total 1735 results

Patrick Boland
Bristol-Myers Squibb; Hoosier Cancer Research Network; Bavarian Nordic

Active, not recruiting

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Metastatic Colorectal Cancer

United States
Bavarian Nordic

Completed

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Metastatic Cancer | Solid Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Small Bowel Cancers | Colorectal Cancers

United States
Bavarian Nordic

Completed

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Bladder Cancer

United States
Georgetown University
National Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaborators

Terminated

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Metastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic Cancer

United States
Immodulon Therapeutics Ltd

Terminated

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (MODULATE)

Metastatic Cancer

France, United Kingdom
National University Hospital, Singapore

Not yet recruiting

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers (VALUE-CHECK)

Carcinoma, Hepatocellular | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Oesophageal Cancer | GastroEsophageal Cancer

Singapore
Bristol-Myers Squibb

Not yet recruiting

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France (URADJ)

Urothelial Carcinoma

France
Osel, Inc.
City of Hope Comprehensive Cancer Center; Miyarisan Pharmaceutical Co., Ltd.

Recruiting

Dose Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab in Advanced Stage Renal Cell Carcinoma

Advanced or Metastatic Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Not yet recruiting

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Colorectal Cancer | Gastroesophageal Cancer

United States
Osel, Inc.
National Cancer Institute (NCI); City of Hope Medical Center; Miyarisan Pharmaceuticals...

Recruiting

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...

United States
University Health Network, Toronto

Not yet recruiting

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Melanoma (Skin)

Canada
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
University of Utah

Not yet recruiting

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (NeoRelapse)

Melanoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
Medical University of Vienna; University Hospital, Essen; Fondazione IRCCS Istituto... and other collaborators

Recruiting

CARE1 Pragmatic Clinical Trial (CARE1)

Metastatic Kidney Carcinoma | Metastatic Kidney Cancer

France
7 Hills Pharma, LLC

Not yet recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Melanoma | Kidney Cancer | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Non Small Cell Lung Cancer | Skin Cancer | Metastasis | Advanced Solid Tumor | Advanced Cancer | Renal Cell Cancer | Hepatocellular Cancer | Mismatch Repair Deficiency | Pleural Mesothelioma | MSI-High | Anaplastic Lymphoma... and other conditions

United States
Case Comprehensive Cancer Center

Not yet recruiting

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma

United States
China Medical University Hospital

Recruiting

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Hepatocellular Carcinoma

Taiwan
Bristol-Myers Squibb

Recruiting

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

United States
Centre Leon Berard
Agenus Inc.

Not yet recruiting

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME)

Gastric Cancer | Metastatic Cancer | Advanced Cancer | MSI-H

France
National Cancer Institute (NCI)

Not yet recruiting

Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
GlaxoSmithKline

Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoplasms

United States, Spain, Korea, Republic of
University Health Network, Toronto

Recruiting

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe)

Cutaneous Melanoma | Mucosal Melanoma | Melanoma Stage IV

Canada
University Medical Center Groningen

Not yet recruiting

Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy (PREDICT)

Locally Advanced Rectal Carcinoma

Netherlands
Inimmune Corporation
Avance Clinical Pty Ltd.

Not yet recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Australia
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Melanoma | Advanced Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Not yet recruiting

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Bristol-Myers Squibb; United States Department of Defense; Cancer Prevention...

Not yet recruiting

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Metastatic Renal Cell Carcinoma

United States
VA Office of Research and Development

Recruiting

Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL)

Non-Small Cell Lung Cancer

United States
Biond Biologics

Not yet recruiting

A Study of BND-35 in Participants With Advanced Solid Tumors

Cancer

Israel
Mayo Clinic

Recruiting

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Malignant Solid Neoplasm | Renal Cell Carcinoma | Hepatocellular Carcinoma | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Head and Neck Squamous... and other conditions

United States
Replimune Inc.

Not yet recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)

Advanced Melanoma
Ono Pharmaceutical Co. Ltd

Recruiting

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Gastric Cancer

Korea, Republic of, Taiwan, Japan
GERCOR - Multidisciplinary Oncology Cooperative...

Not yet recruiting

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer (BIG)

Gastric Cancer
M.D. Anderson Cancer Center

Recruiting

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

ICB-refractory Melanoma

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

Melanoma
UNICANCER
Servier

Not yet recruiting

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer (TRIFLUOX-DP)

Metastatic Colorectal Cancer | Metastatic Gastroesophageal Adenocarcinoma | DPD Deficiency
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab (TURANDORELA)

Neoplasms | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Urinary Bladder Diseases | Male Urogenital Diseases | Female Urogenital Diseases | Urinary Bladder Neoplasm | Female Urogenital Diseases and Pregnancy Complications | Antineoplastics Toxicity | Urogenital Diseases

Netherlands
The Netherlands Cancer Institute

Not yet recruiting

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma (MARIANE)

Melanoma

Netherlands
National Cancer Institute (NCI)

Recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Brigham and Women's Hospital

Not yet recruiting

Drug Screening Using IMD in Bladder Cancer

Muscle Invasive Bladder Urothelial Carcinoma

United States
Dong Bing Zhao

Recruiting

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

Gastric Cancer | Neoadjuvant Therapy | Organoid

China
Exelixis
Arcus Biosciences, Inc.

Recruiting

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

United States
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
Bristol-Myers Squibb

Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Resectable Non-small Cell Lung Cancer

Germany
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (BETTER)

Melanoma Brain Metastases
Fudan University

Recruiting

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer (G/GEJ cancer)

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

China
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Merkel Cell Carcinoma

Australia

Search clinical trials for: CV301, NSCLC, Pembrolizumab, Nivolumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations